Roche Pharmaceutical Development and Sales Overview
Tecentriq (atezolizumab, RG7446)
Anti-PD-L1 cancer immunotherapy - lung cancer
Indication
Adjuvant NSCLC
Periadjuvant NSCLC
Phase/study
# of patients
Design
Phase III
IMpower010
N=1,280
Following adjuvant cisplatin-based chemotherapy
ARM A: Tecentriq
ARM B: Best supportive care
Phase III
IMpower030
N=450
ARM A: Tecentriq plus platinum-based chemotherapy
ARM B: Platinum-based chemotherapy
Primary endpoint
ā
Disease-free survival
Status
CT Identifier
"
"
Trial amended from PD-L1+ selected patients to all-comers
FPI for all-comer population Q4 2016
Recruitment completed Q3 2018
Study met primary endpoint Q1 2021
Data presented at ASCO, WCLC and ESMO 2021
Filed in US (priority review) and EU Q2 2021
Approved in US Q4 2021 and EU Q2 2022
NCT02486718
ā Event-free survival
FPI Q2 2018
Recruitment completed Q3 2021
NCT03456063
NSCLC-non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1; ASCO-American Society of Clinical Oncology; ESMO-European Society for Medical Oncology; WCLC=World Conference on Lung Cancer
66
Roche
OncologyView entire presentation